| Website | ensemblediscovery... |
| Category | BioTech |
| Phone | 617-492-6977 |
| info@ensembledisc... | |
| Employees |
| TOTAL | $15M |
| VENTURE FUNDING TOTAL | $15M |
| Series A, 5/04 Flagship Ventures ARCH Venture Partners Oxford Bioscience Partners | $15M |
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
